- Home
- ANGH vs CVM Comparison
ANGH vs CVM Comparison
Compare ANGH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- CVM
- Stock Information
- Founded
- ANGH 2012
- CVM 1983
- Country
- ANGH United Arab Emirates
- CVM United States
- Employees
- ANGH N/A
- CVM N/A
- Industry
- ANGH Telecommunications Equipment
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANGH Consumer Discretionary
- CVM Health Care
- Exchange
- ANGH Nasdaq
- CVM Nasdaq
- Market Cap
- ANGH 46.8M
- CVM 40.1M
- IPO Year
- ANGH N/A
- CVM 1987
- Fundamental
- Price
- ANGH $0.69
- CVM $0.40
- Analyst Decision
- ANGH
- CVM
- Analyst Count
- ANGH 0
- CVM 0
- Target Price
- ANGH N/A
- CVM N/A
- AVG Volume (30 Days)
- ANGH 18.0K
- CVM 1.2M
- Earning Date
- ANGH 02-28-2025
- CVM 02-14-2025
- Dividend Yield
- ANGH N/A
- CVM N/A
- EPS Growth
- ANGH N/A
- CVM N/A
- EPS
- ANGH N/A
- CVM N/A
- Revenue
- ANGH $52,274,011.00
- CVM N/A
- Revenue This Year
- ANGH N/A
- CVM N/A
- Revenue Next Year
- ANGH N/A
- CVM N/A
- P/E Ratio
- ANGH N/A
- CVM N/A
- Revenue Growth
- ANGH 13.03
- CVM N/A
- 52 Week Low
- ANGH $0.62
- CVM $0.33
- 52 Week High
- ANGH $2.27
- CVM $2.50
- Technical
- Relative Strength Index (RSI)
- ANGH 44.92
- CVM 45.54
- Support Level
- ANGH $0.63
- CVM $0.39
- Resistance Level
- ANGH $0.72
- CVM $0.68
- Average True Range (ATR)
- ANGH 0.05
- CVM 0.06
- MACD
- ANGH 0.00
- CVM 0.01
- Stochastic Oscillator
- ANGH 42.31
- CVM 18.86
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.